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CD44 represent a family of transmembrane glycoproteins. They
are found at the cell surface in many tissues (Higashikawa et al,
1996) and in soluble form in plasma (Lucas et al, 1989). Isoforms
of CD44 are attributed to alternative splicing of a single CD44
gene (Screaton et al, 1992) and post-translational modifications
such as N- and O-glycosylation (Labarrière et al, 1994). Physio-
logically, CD44 is the main cell surface receptor of hyaluronate, an
important component of the extracellular matrix (Aruffo et al,
1990). Consequently, CD44 is involved in a number of various
cell–cell and cell–matrix interactions including lymphocyte migra-
tion and activation (Huet et al, 1989; Galmiche and Lustenberger,
1994; Rafi et al, 1997).
The genomic structure of CD44 reveals a striking degree of
complexity and confirms the role of alternative splicing as the basis
of the structural and functional diversity present in the CD44 mole-
cules. After activation, lymphocytes transiently up-regulate CD44
isoforms expressing variant exons (Arch et al, 1992). The expression
of such variants after transfection of rat CD44 cDNAs containing
exons v6 and v7 confers a metastatic phenotype to non agressive rat
pancreatic adenocarcinoma cell lines (Günthert et al, 1991).
The expression pattern of CD44 has been studied in various
types of tissues and human malignant tumours, for instance in
neuroblastoma (Combaret et al, 1996), in normal colonic mucosa
and colorectal carcinomas (Gorham et al, 1996; Imazeki et al,
1996), in human digestive tract carcinomas and normal tissues
(Higashikawa et al, 1996) and in ovarian cancer (Sliutz et al, 1995).
These studies investigated CD44 gene expression at both RNA and
protein levels. mRNA were analysed by reverse transcription poly-
merase chain reaction (RT-PCR), Southern blotting, or in situ
hybridization. Proteins were studied by immunohistochemistry or
Western blotting using specific antibodies against standard CD44
or variant isoforms. An overexpression of variant or standard CD44
has been described for most cancers (Gorham et al, 1996;
Higashikawa et al, 1996), whereas a down-regulation has been
associated with neuroblastoma progression (Combaret et al, 1996).
As far as colorectal cancer is concerned, the tumour cells and the
cells from the normal mucosa present a similar CD44 alternative
splicing pattern, but the expression level is higher in cancer cells.
CD44 variants that have been associated with malignant transforma-
tion and metastasis, especially CD44v6, are commonly expressed by
normal colonic epithelia, particularly the basal crypt epithelium
(Gotley et al, 1996). The abnormal and elevated CD44 expression
revealed by PCR is a direct product of the cancer cells (Gorham et al,
1996), but no particular CD44 transcript was clearly associated with
colorectal tumour progression (Imazeki et al, 1996). Each variant
exon, from v2 to v10, was detected in tumours independently of their
grade. However, aberrant expression of CD44 is frequent and some
isoforms might have an important role in tumour progression
suggesting a complex role for CD44 in colorectal malignancy.
Colorectal cancer is the second most common cause of death
from malignant disease in Western Europe and North America.
There is a clear need for more sensitive serum markers. As many
cell surface receptors, CD44 is present as a soluble form in extra-
cellular fluids. sCD44 has been measured and partially character-
ized in human plasma (Lucas et al, 1989). In a first report, sCD44
has been proposed to be a valuable indicator of tumour growth in
gastric and colorectal cancer (Guo et al, 1994). The aim of this
work was to analyse, in a prospective study, the concentration and
the molecular mass of sCD44 molecules in the plasma of
colorectal cancer patients.
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Summary Based on the important role of CD44 in tumour progression and metastasis, we evaluated, in a prospective study, plasma-soluble
CD44 (sCD44) as a serum marker in colorectal cancer. Blood plasma specimens from 89 patients with colorectal neoplasm, 22 patients with
a gastrointestinal disease and 23 healthy donors were analysed for quantitation (ELISA assay) and purification of sCD44. The concentration
of sCD44, indicating the concentration of all isoforms, was significantly higher in patients with colorectal cancer and intestinal disease than in
normal individuals, but no significant differences were found between the two groups. We found no association between plasma levels and
staging of the colorectal cancer patients according to Astler and Coller. A two-step batch purification combining ion exchange and
immunoaffinity chromatography, followed by Western blot analysis, revealed a complex pattern with a major band corresponding to the
standard form of CD44 and minor bands that may correspond to larger variant forms. No particular sCD44 isoform was clearly associated with
anatomopathological or biological information.
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Blood plasma specimen
Blood samples were collected in heparinized tubes and
centrifuged. Plasma was aliquoted and stored at –20°C until used.
Samples from 89 patients with colorectal neoplasms were
analysed for quantitation and purification of sCD44. Blood
sampling was performed immediately before the beginning of
surgery. Blood samples collected from 23 healthy donors and 22
patients with gastrointestinal diseases (alcoholic hepatitis, diver-
ticulosis, Crohn’s disease, sigmoiditis, gastric ulcer) were used as
controls.
Monoclonal antibodies
Monoclonal antibodies NaM10-8F4 and NaM77-9D6 were
produced by BALB/c mice immunized with human erythrocytes
(Blanchard et al, 1997). NaM77-9D6 was conjugated to CNBr-
activated Sepharose 4B beads (Amersham Pharmacia Biotech,
Uppsala, Sweden) as described by manufacturer.
Plasma assay
Plasma levels of sCD44 were measured using the CD44std
enzyme-linked immunosorbent assay (ELISA) (Bender
MedSystems, Vienna, Austria). The sCD44std ELISA kit allows
the quantitative detection of all circulating CD44 isoforms
comprising the standard protein and the different isoforms.
CA19-9 and carcinoembryonic antigen (CEA) plasma levels
were determined with commercially available microparticular
enzyme immunoassay (MEIA) kits (Abbot Laboratories, Abbot
Park, IL, USA) according to the manufacturer’s instructions.
Purification of CD44
The CD44 was purified from plasma using Q-Sepharose Fast Flow
anion exchange chromatography (Amersham Pharmacia Biotech,
Uppsala, Sweden) and NaM77-9D6-Sepharose 4B immunoaffinity.
Plasma (150 ml) was diluted fivefold with buffer A (10 mM
phosphate buffer, pH 6.0). The protease inhibitors 4-amidino
phenylmethanesulphonyl fluoride (APMSF) and EDTA were
added to a final concentration of 20 mM and 1 mM respectively. The
Q-Sepharose ion exchanger column (150 ml) was equilibrated in
buffer A. The diluted plasma was applied to the column at a flow
rate of 2 ml min–1. The column was then washed with 500 ml buffer
A and 500 ml buffer B (10 mM phosphate buffer, 0.3 M sodium
chloride, 1 mM EDTA, pH 6.0) Bound proteins were then eluted
with 250 ml buffer C (10 mM phosphate buffer, 1 M sodium
chloride, 1 mM EDTA, pH 6.0). The Q-Sepharose column was
washed and regenerated according to Pharmacia instructions.
The eluate (50 ml) was applied to NaM77-9D6-Sepharose 4B
immunoaffinity column (1 ml) equilibrated in buffer C. The affinity
column was washed with 10 ml buffer C at a flow rate of 1 ml
min–1. Immunoaffinity-purified CD44 was eluted from the column
with 50 mM triethylamine (pH 12.0) and extensively dialysed
against phosphate-buffered saline (PBS). The immunoaffinity
column was then washed and regenerated. The protein concentra-
tion was determined by using the bicinchoninic acid protein assay
(BCA) reagent (Pierce, Rockford, IL, USA). The sCD44 concentra-
tion was determined by using the sCD44std ELISA kit.
A batch-purification was adapted to 1-ml plasma samples. The
sample was mixed with protease inhibitors APMSF and EDTA as
above and was diluted with 5 ml buffer A. Q-Sepharose (1 ml)
equilibrated with buffer A was added to the diluted plasma and
gently mixed for 30 min at room temperature. The Q-Sepharose
was then washed with buffer A (3 ´ 5 ml) and buffer B (2 ml).
Bound proteins were eluted with buffer C (1.5 ml). The eluate was
mixed for 3 h at room temperature with NaM77-9D6-Sepharose
4B (30 ml). The affinity gel was washed with buffer C
(3  ´ 0.15 ml) and immunoaffinity-purified CD44 was eluted with
0.25 ml triethylamine 50 mM, pH 12.0.
Western blot analysis
Proteins were precipitated with trichloracetic acid (20% w/v)
overnight at 4°C. After centrifugation and washing with –20°C
acetone, proteins were dissolved in Laemmli’s sample buffer
without reducing reagent. To determine the size of soluble forms
of CD44 in plasma, the proteins were separated by gradient
(4–10%) sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and detected by immunoblotting.
Proteins were transferred to nitrocellulose membranes. Filters
were saturated for 1 h with non-fat dry milk (3% w/v) in Tris-
buffered saline (TBS) and subsequently incubated with NaM10-
8F4 (diluted 1/200) in TBS supplemented with 1% non-fat dry
milk for 1 h under continuous stirring at room temperature. After
exhaustive rinsing with TBS containing 0.5% Tween-20,
membranes were incubated with alkaline phosphatase-conjugated
goat anti-mouse IgG (Sigma, St Louis, MO, USA) in TBS supple-
mented with 1% non-fat dry milk for 1 h. After washing with TBS
containing 0.5% Tween-20, the protein bands were detected using
BCIP/NBT system (Nitro blue tetrazolium/5-bromo-4-chloro-3-
indolyl phosphate) (Promega, Madison, WI, USA). Prestained
molecular weight markers (Sigma) were used as standards.
RESULTS
Plasma sCD44 measurement
Blood samples were collected before the patients underwent
surgical therapy. The mean age of these patients was 66.3 ± 12.7
years (range 32–93) with 42 women and 47 men. The results of
sCD44 plasma levels (means, medians and standard deviations)
are presented in Table 1.
The measured mean level of healthy donors was 260 ± 43 ng
ml–1. sCD44 plasma levels in patients with colorectal carcinoma or
intestinal diseases were statistically significantly higher than in
healthy controls (P = 0.001). In contrast, we found no significant
difference between sCD44 level in patients with a colorectal
cancer or a gastrointestinal disease.
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Table 1 sCD44 in the plasma of healthy controls and patients
sCD44 ng ml–1
Patients n Mean ± s.d. Range Median
Healthy donors 23 260 ± 43 177–396 252
Colorectal carcinoma 89 304 ± 103 111–747 303
Intestinal diseases 22 337 ± 98 207–597 316The clinical staging of these patients was performed according
to Astler and Coller (1954). Plasma concentrations of tumour
markers CEA and CA19.9 in these samples were also determined.
Plasma levels of sCD44, grouped by age, sex, tumour location,
Astler–Coller’s stage, CEA and CA19.9 plasma levels are shown
in Table 2. No statistically significant differences were found
between sCD44 plasma levels when samples were grouped
according Astler–Coller’s stage. The sCD44 concentration was not
correlated with the CEA or CA19.9 serum levels, using the cut-off
values of 5 ng ml–1 and 37 U ml–1 respectively.
Purification of sCD44
The concentration of sCD44, indicating the concentration of all
isoforms, was significantly higher in colorectal cancer than in
normal individuals, but no association was found between sCD44
and clinical parameters. One possible explanation is that only
some isoforms might play an important role in tumour progres-
sion. To investigate if one isoform was more specifically involved,
isoform-specific ELISA can be used. Alternatively, immunopre-
cipitation and Western blot analysis can lead to the simultaneous
identification of several isoforms. Since no particular CD44
variant exon was clearly associated with colorectal tumour
progression, we decided to analyse the molecular mass of sCD44
molecules in plasma of colorectal cancer patients by immuno-
purification and Western blot analysis.
We first immunoprecipitated sCD44 from plasma using
NaM77-9D6 anti-CD44 antibodies covalently linked to agarose
beads. The immunoprecipitated proteins were then separated by
gradient SDS-PAGE and revealed with NaM10-8F4 anti-CD44
antibodies, followed by anti-mouse immunoglobulins. As shown
in Figure 1 (lane 1), a strong signal was seen. However, when an
irrelevant monoclonal antibody was used for the detection, a
similar pattern was obtained (Figure 1, lane C), indicating that
these proteins bound non-specifically to the immunoaffinity
matrix. No such bands were detected when proteins extracted from
lymphocytes were used as a positive control (Figure 1, lane 2),
indicating that the contaminating proteins originated from plasma.
We therefore included as a first step an anion-exchange
chromatography. Most of the immunoglobulins and other plasma
proteins which bound non-specifically to NaM77-9D6-Sepharose
were removed when the column was washed with 0.3 M sodium
chloride (Figure 2A, lane 1). The final 1 M sodium chloride elution
was found to contain the CD44 molecules, which were further puri-
fied by immunoaffinity chromatography (Figure 2A, lane 2). This
two-step purification procedure resulted in an ~6000-fold purifica-
tion of sCD44 with a final yield of 19% (Table 3). Western blot
analysis of sCD44 purified from the plasma of a healthy donor
revealed the presence of a prominent band with a molecular weight
of 85–95 kDa and larger proteins with molecular weight of 100,
140, 180 and 240 kDa (Figure 2A, lane 2). The most prominent
species of sCD44 and the standard CD44 expressed by lympho-
cytes displayed a similar migration (Figure 2A, lane 3). The addi-
tional immunostained bands of soluble CD44 are larger forms that
may correspond to CD44v and/or to different levels of glycosyla-
tion. Duplicate lane 2, stained with an irrelevant antibody as a nega-
tive control, revealed no non-specific band (Figure 2A, lane C).
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Table 2 sCD44 and clinicobiological parameters of 89 colorectal cancer
patients
sCD44 ng ml–1
Parameter Patients Mean ± s.d. Range Median
Sex
Female 42 303 ± 90 126–501 304
Male 47 305 ± 103 111–747 303
Age (years)
≤ 65 39 297 ± 91 111–513 303
³ 65 50 304 ± 103 111–747 303
Tumour location
Colon 48 318 ± 107 123–747 318
Rectum+sigmoid 34 290 ± 100 111–513 290
Unknown 7
Astler–Coller’s stage
A 6 351 ± 82 213–462 361
B1 13 273 ± 82 129–450 255
B2 26 290 ± 102 123–513 285
C1 2 290 ± 51 219–321 270
C2 30 312 ± 121 111–747 303
D 12 336 ± 66 252–513 327
CEA (ng ml–1)
≤ 5 53 305 ± 101 126–513 294
³ 5 36 305 ± 106 111–747 303
CA 19.9 (U ml–1)
≤ 37 67 295 ± 94 123–513 294
³ 37 22 305 ± 122 111–747 318
Table 3 Purification of soluble CD44
Step Volume sCD44 Proteins sCD44 Purification Yield
(ml) (ng ml–1) (g) (mg) (-fold) (%)
Plasma 150 429 10 64.3 1 100
NaM77-9D6- 4 3000 3.04 10–4 12 6139 19
Sepharose eluate
C1 2
kDa
205
112
87
69
56
Figure 1 Immunopurified sCD44 obtained from plasma of a healthy donor
by NaM77-9D6-Sepharose 4B immunoaffinity chromatography. Staining with
irrelevant antibody as negative control (lane C). Revelation with NaM10-8F4
antibody (lane 1). Lysate of peripheral blood lymphocytes (5 3 105 cells)
used as positive control for CD44std (lane 2)We then scaled down this purification and set up a batch-purifi-
cation of sCD44 from 1-ml plasma sample. As illustrated in Figure
2B, sCD44 purified by column chromatography or batch-wise
presented similar pattern. Duplicate lane 2, stained with irrelevant
antibody as a negative control revealed a faint non-specific band
corresponding to a molecular weight of 150 kDa (Figure 2B, lane
C2). When several samples of the same plasma were subjected to
purification, identical patterns were obtained, indicating that this
procedure is reproducible (data not shown).
sCD44 was purified from 21 colorectal carcinoma patients, ten
intestinal disease patients and six healthy donors. sCD44 size
heterogeneity was observed. All the previous described immuno-
stained bands were revealed but with great differences in intensity.
The patterns obtained for five healthy donors (Figure 3A), five
stage B patients according to Astler–Coller (Figure 3B) and six
stage C patients (Figure 3C) are presented. There is clearly a great
heterogeneity, both in size and intensity of the bands, even for a
homogenous group of patients. This diversity is also important
between healthy donors and disease patients. No immunostained
band seemed to be associated with the presence of tumour. There
is no clear difference between the colorectal carcinoma
Astler–Coller’s stage B patients group and the colorectal carci-
noma Astler–Coller’s stage C patients group, although the hetero-
geneity and the intensity of the bands were greater in the
Astler–Coller’s stage C patients group.
DISCUSSION
Based on the important biological role of CD44 in tumour progres-
sion, several studies have suggested the potential use of soluble
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Figure 2 Western blot analysis of purified sCD44. (A) Non-specific proteins removed by first ion exchange chomatographic step (lane 1). Eluate obtained from
plasma of a healthy donor by two-step column purification (lane 2). Lysate of peripheral blood lymphocytes (5 3 105 cells) used as control for CD44std (lane 3).
Duplicate lane 2 stained with irrelevant antibody as negative control (lane C) (B) Eluate (25 ml) obtained from plasma of a healthy donor by two-step column
purification (lane 1) and eluate from batch purification of 1 ml specimen of the same serum (lane 2). Duplicates lane 1 and lane 2 stained with irrelevant
antibody as negative control (respectively lane C1 and C2)
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Figure 3 Western blot analysis of sCD44 from patients. (A) Five healthy donors, sCD44 concentrations are respectively (1) 237 ng ml–1, (2) 246 ng ml–1, (3)
300 ng ml–1, (4) 294 ng ml–1, (5) 396 ng ml–1; (B) five colorectal cancer Astler–Coller’s stage B patients, sCD44 concentrations are respectively (1) 285 ng ml–1,
(2) 366 ng ml–1, (3) 123 ng ml–1, (4) 303 ng ml–1, (5) 129 ng ml–1; (C) six colorectal cancer Astler–Coller’s stage C patients, sCD44 concentrations are
respectively (1) 321 ng ml–1, (2) 456 ng ml–1, (3) 747 ng ml–1, (4) 309 ng ml–1, (5) 186 ng ml–1, (6) 288 ng ml–1. For each group, a control (plasma pool) stained
with irrelevant antibody as negative control (lane C)CD44 as a marker of disease progression (Guo et al, 1994; De Rossi
et al, 1997; Ristamäki et al, 1998). For instance in ovarian cancer,
the concentration of sCD44std was found to be higher and
sCD44v5 to be lower than in healthy controls (Zeimer et al, 1997).
A lower concentration of CD44v5 has also been reported for
prostate cancer and renal cancer (Jung et al, 1996; Lein et al, 1996).
In the case of renal cancer, another report (Kan et al, 1996) showed
that the concentrations of sCD44std and sCD44 splice isoforms
sharing exon v6 were significantly higher than in normal individ-
uals, but there was no correlation between these concentrations and
clinico-pathological parameters. In breast cancer, plasma sCD44v5
and v6 were significantly elevated in patients with node-positive
breast cancer (Martin et al, 1997). In gastric carcinoma, the concen-
trations of sCD44v5 and v6 were elevated in gastric carcinoma
patients. Moreover, plasma sCD44v5 concentrations correlated
with tumour burden, lymph node involvement and the presence of
metastasis (Harn et al, 1996).
In a first report, Guo et al (1994), using a home-made ELISA
which detects CD44std as well as isoforms, showed that plasma
sCD44 concentration was elevated in advanced colon cancer and
correlated with tumour burden and metastasis. During completion
of our manuscript, a second study demonstrated that both
sCD44std and sCD44v6 levels were significantly higher in
colorectal cancer and chronic inflammatory bowel disease than in
normal individuals (Weg-Remers et al, 1998). The concentrations
of sCD44 we determined for colorectal cancer patients are in
agreement with the values reported by other groups using the same
ELISA kit. Our data show that a significant elevation of plasma
concentrations of sCD44 is found in patients with colorectal
cancer or chronic inflammatory bowel disease when compared to
healthy controls. There is no difference between the two groups of
patients. The sCD44 level is not correlated with the presence of
tumour and does not reflect the neoplastic progression or the
metastatic state.
In order to investigate whether isoforms of sCD44 were associ-
ated with tumour progression or not, we designed an efficient
purification procedure which allowed us to analyse simultaneously
a large number of these variant molecules. This purification can be
distinguished from the previously reported techniques by the
quality of the sCD44 isoforms revealed by immunoblotting. A
major point lies in the use of an anion exchange chromatography,
which allowed us to get rid of contaminant proteins, although the
batch procedure was not as efficient as the column purification.
The main problem encountered in the purification of CD44 is
related to the anionic nature of the protein. In the immunoaffinity
step, the binding of sCD44 onto the immobilized monoclonal anti-
body is not only based on antigen–antibody recognition, but also
on strong ionic interactions between anionic (CD44) and cationic
(Ig) proteins. This led us to use triethylamine 50 mM, pH 12.0 for
the elution step. These conditions preclude the obtention of great
amount of CD44, explaining the somehow limited yield. Finally,
both NaM77-9D6 and NaM10-8F4 epitopes are located on the
constant part of CD44 within the extracellular domain of all CD44
isoforms. Therefore, all isoforms are co-purified and revealed on
the immunoblot.
Purification followed by Western blot analysis revealed a
complex pattern. A major band with molecular weight of 85–
95 kDa corresponding to the standard form of CD44 was always
seen. Minor bands, with molecular weight of 100, 140, 180 and
240 kDa, were not consistently present in the plasma of healthy
donors and colorectal cancer patients. No particular CD44 band
seemed to be associated with colorectal tumour progression. The
sCD44 pattern is not correlated with the presence of tumour and
does not reflect the neoplastic progression or the metastatic state.
The cellular origin of sCD44 isoforms in human plasma is still
unknown. The soluble forms might derive from proteolytic release
of extracellular domain of membranous CD44 or by alternative
splicing. Studies of cell culture medium of lymphocytes or tumour
cells have indicated that sCD44 can be generated, at least in part,
by proteolytic cleavage of membrane-bound CD44 (Ristamäki et
al, 1997), and metalloprotease and serine protease activities have
been shown to be involved in this process (Bazil and Stominger,
1994). In mouse a stop codon within a new exon (v10) provides a
molecular basis for alternative synthesis of sCD44 isoforms (Yu
and Toole, 1996). Synthesis of sCD44 via alternative splicing
provides a mechanism of production that is subject to rigourous
cellular control and thus may be important in the regulation of
CD44 activity. However, shedding from lymphocytes seems to
represent one major origin of the soluble CD44 isolated from
plasma, generating molecules with biological functions compa-
rable to that of the membrane isoforms (Ristamäki et al, 1997).
Cleavage of membrane molecules may represent a mechanism
producing soluble forms that have various regulatory functions
and this process is markedly influenced by the activity of the
immune system (Katoh et al, 1994). So the predominant origin of
sCD44 variants in human plasma might be related to this activity.
It has been proposed that sCD44 may act as an antagonist of
cellular CD44, especially in tumorigenesis and immune responses.
In fact, soluble adhesion molecules might act as antiadhesive
agents. Shedding of CD44 occurs during immune activation, in
inflammatory conditions and in neoplasia. This might explain why
sCD44 levels are elevated in our group of gastrointestinal diseases
patients as well as in the cancer patients group.
Two main processes are responsible for the complex pattern of
sCD44 seen after purification: the alternative splicing of nine
exons; and post-translational modifications such as N- and O-
linked glycosylation, addition of chondroitin, or heparan sulphate
side-chains. In order to determine whether sCD44 isoforms can be
of value in colorectal cancer survey, we will now attempt to
identify these different plasma isoforms and characterize their
glycosylation status.
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